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Thanks to current medical advances, many diseases are 
preventable or curable; however, the emergence of an 
epidemic or pandemic without definitive treatment 
poses a major challenge for the medical community 
and the general population. Severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) an emerging 
disease, common between humans and animals, 
appeared in 2019 and led to COVID-19 (1). 
Coronaviruses are the cause of 15% of respiratory 
diseases and can be transmitted from animal to human 
or vice versa. COVID-19 has high transmissibility; 
also its latency period is long (2). COVID-19 can infect 
individuals through means such as respiratory droplets 
and contact with secretions containing the virus. 
COVID-19 is considered a multi-organic disease. 
Coronaviruses are a family of RNA and other 
Nidovirales. Acquired Immunodeficiency Syndrome 
(AIDS) is a member of the Lentivirus family of animal 
retroviruses, which can cause long-term latent 
infection in cells and short-term cytotoxic effects 
leading to progressive and fatal diseases. Each human 
immunodeficiency virus (HIV) consists of two 
identical single-stranded RNA molecules encoded in 
viral proteins. The virus has the same basic nucleic acid 
sequence as all known retroviruses (3). The hepatitis C 
virus also infects people through similar routes of HIV 
transmission, with an emphasis on blood transfusions. 
It is a member of the Flaviviridae and Hepacivirus (4). 
So far, no approved vaccine has been developed for 
hepatitis C and HIV (5). Currently, more than 120 
million people have been infected and 2.5 million 
deaths due to COVID-19 have been reported 
worldwide; while, the number of people living with 
HIV and hepatitis C are 38 million and 71 million, 
respectively; all being RNA virus-induced diseases. So 
far, no vaccine for hepatitis C and HIV has been 
approved, while in November 2020 Pfizer and 
Moderna (6, 7) announced positive results from the 
analysis of their phase III pilot trials about their 
vaccine against acute respiratory syndrome virus 
(SARS-COV-2). In November 2020, Pfizer and 
Moderna announced positive results in the 
effectiveness of their vaccine against SARS-COV-2 (6, 
7). Pfizer company in collaboration with BioNTech 
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completed a clinical trial to develop a potential RNA 
vaccine to prevent the spread of COVID-19, the two 
companies had been working together in 2018 to 
develop a vaccine against the flu, however, following 
the COVID-19 pandemic, they focused their efforts on 
producing a vaccine for the COVID-19 (7, 8). 
Considering the same importance of COVID-19, AIDS 
and hepatitis C regarding the following: 
 All three are virus-induced viral diseases 
 Their transmission is from human to human 
 The viruses that cause these diseases are in the 
group of RNA viruses 
 The outbreak of these diseases causes 
pandemics and high mortality in the world 
 Finally, COVID-19 and AIDS were originally 
transmitted from animals to humans 
Therefore, with the development of a vaccine for 
COVID-19, it could be a potential window for vaccines 
against AIDS and hepatitis C; these hopes will not be 
far from the expectation. 
 
Conflicts of Interest  
The authors declare that there are no conflicts of 
interest. 
References 
1. Pourhossein B, Dabbagh A, Fazeli M. Insights into the SARS-CoV-
2 Outbreak; the Great Global Challenge: A Mini Review. J Cell Mol 
Anesth. 2020;5(1):23-6. 
2. Wilson ME, Chen LH. Travellers give wings to novel coronavirus 
(2019-nCoV). J Travel Med. 2020;27(2). 
3. Rajaei S, Dabbagh A. The immunologic basis of COVID-19: a 
clinical approach. J Cell Mol Anesth. 2020;5(1):37-42. 
4. Chen Y, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus 
genotypes and subtypes circulating in Mainland China. Emerg 
Microbes Infect. 2017;6(11):e95. 
5. Bailey JR, Barnes E, Cox AL. Approaches, Progress, and 
Challenges to Hepatitis C Vaccine Development. Gastroenterology. 
2019;156(2):418-30. 
6. Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update 
in pipeline vaccines, their design and development strategies. Eur J 
Pharmacol. 2021;892:173751. 
7. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status 
report. Virus Res. 2020;288:198114. 
8. Ng WH, Liu X, Mahalingam S. Development of vaccines for 
SARS-CoV-2. F1000Res. 2020;9. 
 
